View Older Stories View More Recent Stories

Sep 26, 2023 04:00AM MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA Services
Sep 22, 2023 06:46AM Merck (MRK) and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA Plus LENVIMA in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
Sep 22, 2023 06:45AM Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
Sep 22, 2023 06:00AM Merck (MRK) Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival
Sep 22, 2023 06:00AM Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced
Sep 20, 2023 06:45AM Merck (MRK) Granted FDA Priority Review for KEYTRUDA Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Sep 20, 2023 06:45AM FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical
Sep 19, 2023 06:45AM Merck (MRK) Announces FDA Acceptance for Priority Review of NDA for WELIREG
Sep 19, 2023 06:45AM FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
Sep 15, 2023 09:10AM Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based C
Sep 15, 2023 09:10AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Plat
Sep 11, 2023 07:45AM Merck (MRK) Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with PAH
Sep 11, 2023 07:45AM Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)
Sep 7, 2023 06:46AM Merck (MRK) Announces Expanded EU Indication for ERVEBO to Include Children 1 Year of Age and Older
Sep 7, 2023 06:45AM European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older
Sep 5, 2023 08:05AM Merck (MRK) Reports Publication of Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL9
Sep 5, 2023 08:00AM Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL®9 Published in Pediatrics
Sep 5, 2023 06:45AM Merck to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Aug 29, 2023 06:50AM Merck (MRK) Announces EU Approval of KEYTRUDA Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing
Aug 29, 2023 06:50AM European Commission Approves KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma E
Aug 29, 2023 06:45AM Merck to Participate in the Citi 18th Annual BioPharma Conference
Aug 25, 2023 06:31AM Merck (MRK) Initiates Phase 3 Clinical Program for MK-0616
Aug 25, 2023 06:30AM Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616
Aug 25, 2023 06:24AM Merck (MRK) and Eisai Provide Update on Phase 3 LEAP-010 Trial of KEYTRUDA pus LENVIMA
Aug 25, 2023 06:15AM Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squam
Aug 24, 2023 06:45AM Merck (MRK) Reports LYNPARZA Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Aug 24, 2023 06:45AM LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Aug 18, 2023 06:46AM Merck (MRK) Reports WELIREG Phase 3 LITESPARK-005 Trial Met Primary Endpoint
Aug 18, 2023 06:45AM Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
Aug 8, 2023 04:01PM Ligand Reports Second Quarter 2023 Financial Results
Aug 7, 2023 08:30AM Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial
Aug 3, 2023 06:45AM Merck (MRK) Announces FDA Approval of ERVEBO for Use in Children 12 Months of Age and Older
Aug 3, 2023 06:45AM U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older
Aug 1, 2023 06:30AM Merck Announces Second-Quarter 2023 Financial Results
Aug 1, 2023 05:57AM Busy earnings day, Meta reportedly prepares AI chatbot - what's moving markets
Jul 28, 2023 06:45AM Merck (MRK) Reports Phase 3 KEYNOTE-756 Trial Met Primary Endpoint
Jul 28, 2023 06:45AM Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer
Jul 27, 2023 06:45AM Merck (MRK) Announces V116 Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
Jul 27, 2023 06:45AM Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
Jul 26, 2023 06:45AM Merck (MRK) and Moderna (MRNA) Initiate Phase 3 Study Evaluating V940 in Combination with KEYTRUDA
Jul 26, 2023 06:45AM Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
Jul 25, 2023 12:58PM Merck Announces Fourth-Quarter 2023 Dividend
Jul 21, 2023 07:52AM Merck (MRK) Receives Positive European Union CHMP Opinion for Gefapixant
Jul 21, 2023 07:52AM Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinom
Jul 21, 2023 07:52AM Merck Receives Positive European Union CHMP Opinion for Gefapixant
Jul 21, 2023 07:50AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) A
Jul 19, 2023 06:46AM Merck (MRK) Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS)
Jul 19, 2023 06:45AM Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Jul 17, 2023 08:45AM Argus adds Adobe (ADBE), Merck (MRK), Tesla (TSLA), Walmart (WMT) to its Focus List
Jul 12, 2023 11:30AM MilliporeSigma Invests $25 Million to Expand Cell Culture Media Production in Kansas
View More Recent Stories View Older Stories